Trial Profile
A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cholangiocarcinoma; Head and neck cancer; Leiomyosarcoma; Liver cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 15 Dec 2021 Results published in the International Journal of Cancer
- 28 Apr 2020 Interim results presented at the 111th Annual Meeting of the American Association for Cancer Research - I
- 04 Feb 2020 Status changed from active, no longer recruiting to completed.